Who is sponsoring NCT04686669?

NCT04686669 is sponsored by Forendo Pharma Ltd.

What drugs are being tested in NCT04686669?

Interventions in NCT04686669: FOR-6219 capsule formulation, FOR-6219 tablet formulation.

What condition does NCT04686669 study?

NCT04686669 studies Relative Bioavailability.

Is NCT04686669 still recruiting?

NCT04686669 is currently completed. Last updated 29 January 2021.

Last reviewed 2021-01-29 · How we verify

NCT04686669

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Relative Bioavailability Study of FOR-6219 in Capsule and Tablet Formulations

Completed Phase 1 Last updated 29 January 2021

What this trial tests

Phase 1 trial testing FOR-6219 capsule formulation in Relative Bioavailability in 12 participants. Completed in 16 January 2021.

Timeline

10 December 2020

Primary endpoint
16 January 2021

16 January 2021

Quick facts

Lead sponsor	Forendo Pharma Ltd
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	none
Primary purpose	other
Enrollment	12
Start date	10 December 2020
Primary completion	16 January 2021
Estimated completion	16 January 2021
Sites	1 location across United Kingdom

Drugs / interventions tested

FOR-6219 capsule formulation
FOR-6219 tablet formulation

Conditions studied

Relative Bioavailability — all drugs for Relative Bioavailability →

Sponsor

Forendo Pharma Ltd — full company profile →

Who can join

Adults 45 to 65, female only, with Relative Bioavailability. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a phase 1, randomised, open-label, three-way, three-period, crossover relative bioavailability study to assess the single-dose pharmacokinetics of FOR-6219 in capsule and tablet formulations in postmenopausal women. The effect of high-fat food on the pharmacokinetics of the tablet formulation will also be evaluated. A total of twelve, post-menopausal women, will be randomised to receive a single oral dose of FOR-6219 in three treatment periods: capsule formulation (fasted); tablet formulation (fed); tablet formulation (fasted)

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Targeting the formation of estrogens for treatment of hormone dependent diseases-current status.
Rižner TL, Romano A. · · 2023 · cited 16× · PMID 37188267 · DOI 10.3389/fphar.2023.1155558

Verify or expand the search:

Other Forendo Pharma Ltd trials

Trials by the same sponsor.

NCT03709420 — A Study to Investigate the Safety, Tolerability, Food Effect, Pharmacokinetics and Pharmacodynamics of FOR-6219 · Phase 1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04686669 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Forendo Pharma Ltd
Last refreshed: 29 January 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04686669.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing